Impact of sodium glucose co-transporter 2 inhibitors on bleeding, hospitalizations and other adverse outcomes in atrial fibrillation patients with and without diabetes
{{output}}
Introduction: Emerging evidence suggests that sodium glucose co-transporter 2 inhibitors (SGLT2i ) may be associated with a reduced risk of arrhythmias and associated complications. ... ...
